Vinorelbine Tartrate
Vinorelbine Tartrate is an antitumor drug.
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to
24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
PLoS One.2022, 17(6):e0268505.
Process Biochemistry2019, 85:106-115
Processes2021, 9(1), 153;
J Korean Med Obes Res.2023, 23:10-7
Evid Based Complement Alternat Med.2021, 2021:5023536.
FASEB J.2019, 33(8):9685-9694
Nutrients.2023, 15(13):2960.
Molecules.2021, 26(9):2791.
J Sci Food Agric.2023, 103(1):213-220.
Food Res Int.2022, 157:111207.
Related and Featured Products
Am J Hosp Pharm. 1994 Feb 15;51(4):495-9.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.[Pubmed:
8017415]
The compatibility of Vinorelbine Tartrate with selected drugs during simulated Y-site administration was studied.
METHODS AND RESULTS:
A 5-mL sample of Vinorelbine Tartrate 1 mg/mL in 0.9% sodium chloride injection was combined with a 5-mL sample of each of 91 other drugs at concentrations used clinically. Each combination was prepared in duplicate, with the order of mixing being reversed between the two; storage was in constant fluorescent light at 22 degrees C. The admixtures were examined visually in normal fluorescent light and with a Tyndall beam at zero, one, and four hours after preparation. A turbidimeter was used to measure the turbidity of each drug combination at the same intervals. Samples showing visual or turbidimetric evidence of incompatibility were subjected to particle counting and sizing. The majority of the drugs tested were compatible with Vinorelbine Tartrate; most combinations had a turbidity of less than 0.1 nephelometric turbidity unit. Turbidity measurements showed that cefazolin sodium, ceforanide, and cefuroxime sodium were incompatible with Vinorelbine Tartrate.
Visual observation showed incompatibility of Vinorelbine Tartrate with acyclovir sodium, aminophylline, amphotericin B, ampicillin sodium, cefoperazone sodium, ceforanide, cefotetan sodium, ceftriaxone sodium, fluorouracil, furosemide, ganciclovir sodium, methylprednisolone sodium succinate, mitomycin, piperacillin sodium, sodium bicarbonate, thiotepa, and trimethoprimsulfamethoxazole.
CONCLUSIONS:
Vinorelbine Tartrate 1 mg/mL in 0.9% sodium chloride injection was compatible with the majority of the drugs tested for up to four hours at 22 degrees C but was incompatible with 19 drugs.
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy Volume 19, Issue 8, pages 992–994, August 1999
Vinorelbine Tartrate-Induced Pulmonary Edema Confirmed on Rechallenge[Reference:
WebLink]
A 67-year-old woman with metastatic breast cancer experienced sudden and profound pulmonary edema within 45 minutes after completion of intravenous administration of Vinorelbine Tartrate on two occasions. Both times the drug was discontinued and the patient was treated aggressively with oxygen, intravenous furosemide, and a vasodilator. The patient suffered no lasting medical complications due to the reaction. Until clear documentation and the mechanism for occurrence of this reaction are known, patients receiving vinorelbine should be monitored closely, particularly in the first few hours after intravenous administration.
《Journal of Ningxia Medical University》 2010-07
The Protection Effects of Matrine on Vinorelbine Tartrate Induced Venous Injury[Reference:
WebLink]
To explore the protection effect of the Matrine on antitumor drug-Vinorelbine Tartrate Injection induced venous injury.
METHODS AND RESULTS:
The auricular venous injury model of rabbits was established by intravenous infusion of VTI.Different methods were selected to treat the injury: applying Matrine and applying MgSO4.The injury status of the veins and peripheral tissues were observed and HE stain were performed after 48 hours and 7 days treatment,respectively.the histopathological features of the veins and peripheral tissues were analyzed. After comparing the histopathological results of the samples among the 3 groups,the venous injury of the Matraine group was the least severe one in aspect of Lumen hyperemia,inflammatory cell infiltration,bleeding of the perivascular for past 48 hours treatment(P0.05);for post 7days treatment,the venous injury of the Matraine group was the least severe one in aspect of inflammatory cell infiltration,bleedingof the perivascular(P0.05);the subsidence of the venous injury of the Matraine group was the earliest one(P=0.000).
CONCLUSIONS:
Matrine is an effective method on prevention of the antitumor drug Vinorelbine Tartrate induced venous injury.
